alt

XIX International AIDS Conference (AIDS 2012)

July 2012, Washington, DC

AIDS 2012: Adolescent Antiretroviral Options Expanding

A range of new antiretroviral drugs are in development for adolescents with HIV, a population which may have extensive experience with antiretroviral therapy and resistance to some of the most commonly used drugs, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV-infected infants and children. alt

Read more:

AIDS 2012: Studies Shed Light on Inflammation and Immune Activation in People with HIV

HIV and aging was a major medical themes at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. A growing body of evidence indicates that inflammation and excessive immune activation contribute to cardiovascular disease and other non-AIDS conditions in people with HIV as they live to older ages, despite viral suppression on antiretroviral therapy (ART). Several studies presented at the conference looked at the causes and consequences of inflammation in this population. alt

Read more:

AIDS 2012: Aspirin Dampens Immune Activation in HIV+ People on ART

Taking a daily aspirin reduces immune activation and activity of platelets -- the cells responsible for blood clotting -- which may help counteract the increased risk of cardiovascular problems among people with HIV taking antiretroviral therapy (ART), researchers reported at the XIX International AIDS Conference (AIDS 2012) last week in Washington, DC. alt

Read more:

AIDS 2012: Human Papillomavirus Doubles Risk of HIV infection

Pre-existing human papillomavirus (HPV) infection is associated with a 2-fold increase in the risk of HIV acquisition in women, and risk also rose for both heterosexual and gay/bisexual men, according to an 8-study review presented at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC, and published in the August 7, 2012, advance online edition of AIDS.alt

Read more:

AIDS 2012: HPTN 052 Continues to Show Clinical Benefits of Earlier Antiretroviral Therapy

The HPTN 052 trial, best known for showing that early antiretroviral therapy (ART) can dramatically reduce the risk of HIV transmission within serodiscordant couples, also found that early treatment reduces the risk of clinical events and death, though the benefit was largely driven by extrapulmonary tuberculosis, researchers reported recently at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

Read more: